NCT06792487Recruiting
Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23)
Analysis of the Immune Infiltrate in Lesional Skin During Anti-interleukin 23 (IL-23) Therapy in Patients With Moderate-severe Plaque Psoriasis
Source: ClinicalTrials.gov · Last updated 24 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Psoriasis is an immune-mediated inflammatory skin disease characterized by the presence of erythematous and itchy plaques. Psoriasis has a multifactorial pathogenesis, environmental and genetic factors contribute to its development. Although interleukin-23 blockade has been shown to be highly effective in the treatment of psoriasis, relapses have occurred during therapy. Our study aims to identify the cellular source of key cytokines involved in disease recurrence or persistence of at least one psoriatic lesion in patients affected by moderate- severe psoriasis treated with an anti-IL-23 biologic drug. The immune infiltrate of resistant or relapsed plaques during anti-IL-23 therapy will be analysed from skin biopsies.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 26 Jan 2024
- Start date
- 4 Sept 2024
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Diseases
- Psoriasis
- NCT number
- NCT06792487
What you commit to
- Study type: Observational
- Planned participants: 20
- From 4 Sept 2024 to the primary completion date, 1 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- patients with complete response to anti IL23, without resistant plaques or disease flare-ups
Other
- patients unable to express informed consent
Who the study is looking for
- moderate-severe psoriasis PASI\>10
- anti IL 23 biologic therapy for at least 6 months (for the group under treatment)
- during therapy at least one area resistant to treatment or at least one flare of disease (for the group under treatment)
- patients able to express informed consent
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Dermatologia Coordinator of this site? Confirm its status | Rome | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.